Tri-Cities Tech Business Update
IsoRay announces new use of Cesium-131
IsoRay, Inc., based in Richland, Wash., announced that for the first time, Cesium-131 brachytherapy seeds have been implanted for the treatment of colon cancer. The implant was performed at Weill Cornell Medical Center in October. Cesium-131 was chosen based on its short half life and higher dose rate, which allows 99.8% of the treatment dose to be delivered by the time the sutures and mesh dissolve. IsoRay is the sole producer of the Cesium-131 brachytherapy seed, which is also currently used in the treatment of prostate cancer and ocular melanoma among other cancerous conditions. Contact Dwight Babcock at 520-240-4840.
